RG6648

Antibody–drug conjugate

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

1 other tracked programme targets this mechanism.

This drug's own stage for Advanced Solid Tumors: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RG6648: this drugStage not on recordAntibody–drug conjugatec-METnot yet gradedNo reviewed efficacy summary in this indication
AZD4956
Phase 1/2(overall)
Small moleculePOLQ (DNA polymerase theta)not yet gradedNo reviewed efficacy summary in this indication
BMS-986517Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BMS-986548
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-6768Phase 1/2UndisclosedFibroblast Activation Protein (FAP)not yet gradedNo reviewed efficacy summary in this indication
HRS-8364Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Palacaparib
Phase 1/2(overall)
Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
REGN10597Phase 1/2Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
SHR-1681Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4298
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4375Phase 1/2Antibody–drug conjugateTissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF)not yet gradedNo reviewed efficacy summary in this indication
SHR-4610Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-7787Phase 1/2Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
SHR-9803Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-188
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-505
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ABBV-253Phase 1Biologic (subtype unspecified)c-METnot yet gradedNo reviewed efficacy summary in this indication
BMS-986500Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5533524Phase 1Antibody–drug conjugateMUC16not yet gradedNo reviewed efficacy summary in this indication
HRS-6093Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JNJ-87890387Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JNJ-89862175Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
MP0310Phase 1Protein / enzyme therapeuticFAP x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
SHR-3821Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4685
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4849Phase 1Antibody–drug conjugateDLL3not yet gradedNo reviewed efficacy summary in this indication
SHR-7782
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-168
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
YS-ON-001Phase 1Biologic (subtype unspecified)TLR3 (poly I:C adjuvant)not yet gradedNo reviewed efficacy summary in this indication
225Ac-ETN029
—(overall)
Radioligand Therapy (actinium-225)DLL3not yet gradedNo reviewed efficacy summary in this indication
AAA614
—(overall)
Radioligand TherapyFibroblast Activation Protein (FAP)not yet gradedNo reviewed efficacy summary in this indication
AZD5863
—(overall)
Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD9793
—(overall)
Multispecific antibodyGlypican-3 (GPC3) x CD3not yet gradedNo reviewed efficacy summary in this indication
BMS-986506
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GCJ904
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5460025
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
PF-08032560
—(overall)
Small moleculeKAT6A/KAT6B and KAT7not yet gradedNo reviewed efficacy summary in this indication
PF-08046044
—(overall)
Antibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
RG6505
—(overall)
UndisclosedRAS (pan-RAS, RAS-mutant tumors)not yet gradedNo reviewed efficacy summary in this indication
RG6620
—(overall)
UndisclosedKRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.